11:59:10 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-12-05 Årsstämma 2025
2024-11-05 Bokslutskommuniké 2024
2024-08-20 Kvartalsrapport 2024-Q3
2024-05-13 X-dag halvårsutdelning COLO B 5
2024-05-07 Kvartalsrapport 2024-Q2
2024-02-09 Kvartalsrapport 2024-Q1
2023-12-08 X-dag halvårsutdelning COLO B 16
2023-12-07 Årsstämma 2024
2023-11-09 Bokslutskommuniké 2023
2023-08-17 Kvartalsrapport 2023-Q3
2023-05-15 X-dag halvårsutdelning COLO B 5
2023-05-11 Kvartalsrapport 2023-Q2
2023-02-03 Kvartalsrapport 2023-Q1
2022-12-02 X-dag halvårsutdelning COLO B 15
2022-12-01 Årsstämma 2023
2022-11-07 Bokslutskommuniké 2022
2022-08-17 Kvartalsrapport 2022-Q3
2022-05-09 X-dag halvårsutdelning COLO B 5
2022-05-05 Kvartalsrapport 2022-Q2
2022-01-25 Kvartalsrapport 2022-Q1
2021-12-03 X-dag halvårsutdelning COLO B 14
2021-12-02 Årsstämma 2022
2021-11-01 Bokslutskommuniké 2021
2021-08-18 Kvartalsrapport 2021-Q3
2021-05-10 X-dag halvårsutdelning COLO B 5
2021-05-06 Kvartalsrapport 2021-Q2
2021-02-06 Kvartalsrapport 2021-Q1
2020-12-04 X-dag halvårsutdelning COLO B 13
2020-12-03 Årsstämma 2021
2020-11-03 Bokslutskommuniké 2020
2020-08-18 Kvartalsrapport 2020-Q3
2020-05-11 X-dag halvårsutdelning COLO B 5
2020-05-06 Kvartalsrapport 2020-Q2
2020-02-06 Kvartalsrapport 2020-Q1
2019-12-06 X-dag halvårsutdelning COLO B 12
2019-12-05 Årsstämma 2020
2019-11-05 Bokslutskommuniké 2019
2019-08-14 Kvartalsrapport 2019-Q3
2019-05-06 X-dag halvårsutdelning COLO B 5
2019-05-02 Kvartalsrapport 2019-Q2
2019-02-05 Kvartalsrapport 2019-Q1
2018-12-06 X-dag halvårsutdelning COLO B 11
2018-12-05 Årsstämma 2019
2018-11-01 Bokslutskommuniké 2018
2018-08-08 Kvartalsrapport 2018-Q3
2018-05-07 X-dag halvårsutdelning COLO B 5
2018-05-03 Kvartalsrapport 2018-Q2
2018-02-01 Kvartalsrapport 2018-Q1
2017-12-08 X-dag halvårsutdelning COLO B 10.5
2017-12-07 Årsstämma 2018
2017-11-02 Bokslutskommuniké 2017
2017-08-16 Kvartalsrapport 2017-Q3
2017-05-08 X-dag halvårsutdelning COLO B 4.5
2017-05-03 Kvartalsrapport 2017-Q2
2017-02-01 Kvartalsrapport 2017-Q1
2016-12-06 X-dag halvårsutdelning COLO B 9
2016-12-05 Årsstämma 2017
2016-11-02 Bokslutskommuniké 2016
2016-08-16 Kvartalsrapport 2016-Q3
2016-05-09 X-dag halvårsutdelning COLO B 4.5
2016-05-03 Kvartalsrapport 2016-Q2
2016-02-02 Kvartalsrapport 2016-Q1
2015-12-10 X-dag halvårsutdelning COLO B 8
2015-12-09 Årsstämma 2016
2015-11-03 Bokslutskommuniké 2015
2015-08-11 Kvartalsrapport 2015-Q3
2015-05-07 X-dag halvårsutdelning COLO B 4.5
2015-05-05 Kvartalsrapport 2015-Q2
2015-01-29 Kvartalsrapport 2015-Q1
2014-12-05 X-dag halvårsutdelning COLO B 7.5
2014-12-04 Årsstämma 2015
2014-10-30 Bokslutskommuniké 2014
2014-05-08 X-dag halvårsutdelning COLO B 4
2013-12-06 X-dag halvårsutdelning COLO B 7
2013-12-05 Årsstämma 2014
2013-10-31 Bokslutskommuniké 2013
2013-08-13 Kvartalsrapport 2013-Q3
2013-05-06 X-dag halvårsutdelning COLO B 3
2013-04-30 Kvartalsrapport 2013-Q2
2013-01-30 Kvartalsrapport 2013-Q1
2012-12-19 Split COLO B 1:5
2012-12-11 Årsstämma 2013
2012-11-06 Bokslutskommuniké 2012
2012-08-15 Kvartalsrapport 2012-Q3
2012-04-26 Kvartalsrapport 2012-Q2
2012-01-25 Kvartalsrapport 2012-Q1
2011-12-08 X-dag ordinarie utdelning COLO B 14.00 DKK
2011-12-07 Årsstämma 2012
2011-11-01 Bokslutskommuniké 2011
2011-08-17 Kvartalsrapport 2011-Q3
2011-06-21 Kapitalmarknadsdag 2011
2011-05-04 Kvartalsrapport 2011-Q2
2011-01-26 Kvartalsrapport 2011-Q1
2010-12-02 X-dag ordinarie utdelning COLO B 10.00 DKK
2009-12-02 X-dag ordinarie utdelning COLO B 7.00 DKK
2004-12-16 Split COLO B 1:2

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriMedicinteknik
Coloplast är verksamt inom medicinteknik. Bolaget är en utvecklare av produkter och tjänster anpassade för människor med olika medicinska tillstånd. Bolagets produktportfölj består av vårdutrustning och används huvudsakligen inom områdena stomi, inkontinens, urologi, samt hud- och sårvård. Idag är bolaget verksamma på en global marknad via egna försäljningskanaler. Bolaget grundades 1954 och har sitt huvudkontor i Humlebæk, Danmark.
2023-02-03 07:35:06

The new intermittent catheter Luja™ addresses important risk factors for urinary tract infections, a significant burden for people using intermittent catheters as well as healthcare systems as a whole.

Urinary tract infections represent a significant challenge for people who use intermittent catheters to empty their bladder. This includes people living with spinal cord injury, multiple sclerosis, or spina bifida. On average, intermittent catheter users have 2-3 urinary tract infections per year1-3, which can lead to serious health complications4, have a significant impact on quality of life2, and result in hospitalisation5-9, thereby putting pressure on local healthcare systems.


Complete bladder emptying in one free flow

Coloplast is now launching Luja, the first and only male catheter featuring 80+ micro-holes, aiming to address important UTI risk factors1 linked to intermittent catheterisation.

“The primary function of a catheter is to empty the bladder. Still, people experience urine flow stops and blockage of the catheter eyelets during bladder emptying with the conventional catheters on the market today10”, says Executive Vice President of Innovation at Coloplast, Nicolai Buhl.

Flow stops and blockage of the catheter eyelets during emptying increase the risk of leaving residual urine behind in the bladder. Residual urine increases the risk of bacteria growth and is a well-known UTI risk factor1.

“With Luja and its Micro-hole Zone Technology we are setting a new standard for intermittent catheterisation and ensuring complete bladder emptying in one free flow*. We believe this catheter will be a paradigm shift within continence care and benefit catheter users as well as healthcare systems as a whole,” ends Nicolai Buhl.

The launch of Luja begins this month, February, in Denmark and Finland, and the product is expected to be available across Coloplast’s key markets over the next 12 months. Coloplast is currently conducting two pivotal clinical studies to document and demonstrate the benefits of Luja. The results are expected to be publicly available within the next few months.


A growth driver in continence care

In 2021/22, the global market for continence care products was worth an estimated 15-16 billion DKK with an underlying annual market growth of 5-6%. Coloplast is the global market leader in continence care, and the company continues to outgrow the market and take market share. The launch of Luja is expected to contribute to Coloplast’s growth trajectory and help solidify the company’s global market leader position.

* Luja has close to no flow stops and complete bladder emptying is defined as <10 mL (CP353, NCT05485922)

CONTACTS

Peter Mønster
Sr. Media Relations Manager, Corporate Communications
+45 4911 2623
dkpete@coloplast.com


Aleksandra Dimovska
Director, Investor Relations
+45 4911 2458
dkadim@coloplast.com


 

  1. Kennelly M, Thiruchelvam N, Averbeck MA, Konstatinidis C, Chartier-Kastler E, Trøjgaard P, et al. Adult Neurogenic Lower Urinary Tract Dysfunction and Intermittent Catheterisation in a Community Setting: Risk Factors Model for Urinary Tract Infections. Adv Urol. 2019;2019:2757862.
  2. Islamoska S, Landauro MH, Zeeberg R, Jacobsen L, Vaabengaard R. Patient-reported risk factors for urinary tract infections are associated with lower quality of life among users of clean intermittent catheterisation.  BAUN; Edinburgh2022.
  3. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269-84.
  4. Salomon J, Gory A, Bernard L, Ruffion A, Denys P, Chartier-Kastler E. [Urinary tract infection and neurogenic bladder]. Prog Urol. 2007;17(3):448-53.
  5. Biering-Sørensen F, Bagi P, Høiby N. Urinary tract infections in patients with spinal cord lesions: treatment and prevention. Drugs. 2001;61(9):1275-87.
  6. Biering-Sørensen F. Urinary tract infection in individuals with spinal cord lesion. Curr Opin Urol. 2002;12(1):45-9.
  7. Scotland KB, Lange D. Prevention and management of urosepsis triggered by ureteroscopy. Res Rep Urol. 2018;10:43-9.
  8. Gabbe BJ, Nunn A. Profile and costs of secondary conditions resulting in emergency department presentations and readmission to hospital following traumatic spinal cord injury. Injury. 2016;47(8):1847-55.
  9. The 2021 Annual Statistical Report. Complete Public Version for the Spinal Cord Injury Model Systems. National Spinal Cord Injury Statistical Center, Birmingham, Alabama; 2021.
  1. Tentor F, Grønholt Schrøder B, Nielsen S, Schertiger L, Stærk K, Emil Andersen T, et al. Development of an ex-vivo porcine lower urinary tract model to evaluate the performance of urinary catheters. Sci Rep. 2022;12(1):17818.